ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
三倍做多標普生物-Direxion
335.54
+27.21
8.82%
盤後：
335.94
0.4000
+0.12%
19:59 EDT
成交量：
45.77萬
成交額：
1.52億
市值：
7.13億
市盈率：
- -
高：
340.20
開：
317.82
低：
317.82
收：
308.33
52周最高：
341.93
52周最低：
66.95
股本：
212.45萬
流通股本：
212.45萬
量比：
0.91
換手率：
21.54%
股息：
1.02
股息率：
0.30%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
醫療保健板塊動態：市場快評
投资观察
·
08/05
上海國投先導聯合領投，NewPro完成數千萬元PreA輪融資並獲得乳鐵蛋白FDA Self-GRAS認證
智通财经
·
08/04
FDA授予Xellsmart帕金森病現貨型細胞療法快速通道資格
环球市场播报
·
08/04
艾伯維（ABBV）保妥適新適應症獲FDA受理 有望成美國首款咬肌突出醫美肉毒製劑
金吾财讯
·
08/04
海西新藥(02637.HK)：HX9428治療新生血管性年齡相關性黃斑變性獲美國FDA IND批准啓動II期臨床試驗 同時在中國啓動第二項採用陽性對照的II期臨床試驗
智通财经
·
08/04
海西新藥(02637)：HX9428治療新生血管性年齡相關性黃斑變性獲美國FDA IND批准啓動II期臨床試驗 同時在中國啓動第二項採用陽性對照的II期臨床試驗
智通财经
·
08/04
美國 FDA 授予再鼎醫藥靶向 DLL3 抗體藥物偶聯物 Zocilurtatug Pelitecan（Zoci）孤兒藥資格認定，用於治療神經內分泌癌（NEC）
美通社
·
08/04
醫療健康板塊快訊：市場動態一覽
投资观察
·
08/04
醫療保健板塊綜述：市場快訊
投资观察
·
08/04
美國人已經為多肽而瘋狂，這是你可能關心的5個問題
虎嗅APP
·
08/03
醫療保健動態：市場快訊
投资观察
·
08/03
天智航「蛇吞象式」收購拖累報表？三大疑問待解 遭投資者用腳投票
新浪证券
·
08/03
醫渡科技(02158)聯合南大一附院發布兩款醫療健康智能體 賦能急救教學與心血管科普
智通财经
·
08/03
【今日主題前瞻】AI醫療健康解決方案市場規模2030年或突破1000億元
中金财经
·
08/03
醫療保健板塊速覽：市場動態追蹤
投资观察
·
08/01
諾華宣佈Pluvicto獲FDA批准用於PSMA陽性轉移性激素敏感性前列腺癌，有望推動轉移性前列腺癌治療新標準。
智通财经
·
08/01
Replimune抗癌療法獲FDA專家委員會支持，盤後股價飆升127%
环球市场播报
·
07/31
和諧健康被投保人告上法庭 原因竟是扣費失敗引起
市场资讯
·
07/31
泰德醫藥(03880)成功完成HEPCLUDEX®原料藥之美國FDA上市許可前檢查(PLI)
智通财经
·
07/31
泰德醫藥(03880.HK)成功完成HEPCLUDEX®原料藥之美國FDA上市許可前檢查(PLI)
智通财经
·
07/31
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/LABU/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":335.54,"timestamp":1787688000000,"preClose":308.33,"halted":0,"volume":457661,"hourTrading":{"tag":"盘后","latestPrice":335.94,"preClose":335.54,"latestTime":"19:59 EDT","volume":4196,"amount":1407780.9058,"timestamp":1787702372496,"change":0.4,"changeRate":0.001192,"amplitude":0.002801},"delay":0,"changeRate":0.08824960269840768,"floatShares":2124486,"shares":2124486,"eps":0,"marketStatus":"未開盤","change":27.21,"latestTime":"08-25 16:00:00 EDT","open":317.82,"high":340.1999,"low":317.82,"amount":152177225.23880002,"amplitude":0.072584,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":308.33,"sharesOutstanding":3074486,"nav":307.714,"aum":638348472.96,"dividendRate":0.003032,"bidAskSpread":0.003147,"preHourTrading":{"tag":"盘前","latestPrice":320.4,"preClose":308.33,"latestTime":"09:29 EDT","volume":4090,"amount":1297999.7005999999,"timestamp":1787664599999,"change":12.07,"changeRate":0.039146,"amplitude":0.037817},"postHourTrading":{"tag":"盘后","latestPrice":335.94,"preClose":335.54,"latestTime":"19:59 EDT","volume":4196,"amount":1407780.9058,"timestamp":1787702372496,"change":0.4,"changeRate":0.001192,"amplitude":0.002801},"volumeRatio":0.907558,"impliedVol":0.9895,"impliedVolPercentile":0.796},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2124486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.907558,"shares":2124486,"dividePrice":1.0175,"high":340.1999,"amplitude":0.072584,"preClose":308.33,"low":317.82,"week52Low":66.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":335.54,"eps":0,"divideRate":0.003032,"volume":457661,"delay":0,"ttmEps":0,"open":317.82,"prevYearClose":159.39,"prevWeekClose":317.2,"prevMonthClose":227.4,"prevQuarterClose":292.1,"fiveDayClose":289.98,"twentyDayClose":242,"sixtyDayClose":195.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1122423549","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1122423549","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122423549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 00:26","pubTimestamp":1785860812,"startTime":"0","endTime":"0","summary":"**GSK新品上市，能否化解明年风险？GSK近期推出了血癌药物Blenrep和哮喘治疗药Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，上月也已获得美国批准。0123 ET - 摩根大通分析师在研报中表示，费森尤斯医疗第二季度业绩超出市场预期，但公司重申全年指引，暗示未来几个季度盈利可能收缩。这家德国透析专科公司公布的季度调整后营业利润为5.69亿欧元，高于市场普遍预期的5.14亿欧元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4581","LABU","BK4588","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554061","title":"上海國投先導聯合領投，NewPro完成數千萬元PreA輪融資並獲得乳鐵蛋白FDA Self-GRAS認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554061?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 22:18","pubTimestamp":1785853106,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656875551","title":"FDA授予Xellsmart帕金森病現貨型細胞療法快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2656875551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656875551?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 21:07","pubTimestamp":1785848846,"startTime":"0","endTime":"0","summary":"XellSmart专有的现货型iPSC衍生细胞疗法XS411获得美国FDA快速通道资格，标志着其全球临床开发的重要里程碑。 2026年7月28日，XellSmart宣布，其自主研发的针对帕金森病的同种异体、现货型、可注射iPSC衍生细胞疗法候选产品XS411，已正式获得美国食品药品监督管理局授予的快速通道资格。这一监管认定彰显了美国卫生监管机构对XS411临床价值及其解决帕金森病治疗中重大未满足临床需求潜力的认可，是其全球临床开发和未来市场准入的关键里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeknz5555117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4585","LABU","CNCR","BK4588","WDNA","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656597285","title":"艾伯維（ABBV）保妥適新適應症獲FDA受理 有望成美國首款咬肌突出醫美肉毒製劑","url":"https://stock-news.laohu8.com/highlight/detail?id=2656597285","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656597285?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 21:03","pubTimestamp":1785848630,"startTime":"0","endTime":"0","summary":"艾伯维表示，本次申报是对成熟产品潜力的进一步挖掘，以此匹配不断变化的求美者需求。作为医美赛道重磅单品，新适应症如若获批，有望进一步巩固艾尔建美学在注射医美领域的市场地位。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NmRmY2E4Njg2ODIwNjk0NjU5Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NmRmY2E4Njg2ODIwNjk0NjU5Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","IE000BZT7R73.USD","IE000SO60NU8.SGD","LU1989772923.USD","RXL","LU2129689431.USD","ABBV","BK4588","VHT","LU1496350502.SGD","LU1670627923.USD","LU2433249047.HKD","SG9999015952.SGD","LU2129689605.HKD","XLV","LU0965509010.AUD","PJP","FHLC","AGNG","GLAM","SG9999015945.SGD","LU0738911758.USD","PPH","LU1670628061.USD","LU0708994859.HKD","IYH","LU0158827948.USD","LU0820561818.USD","LU1989771016.USD","LU0320765646.SGD","TRUH","IE000MB6IJN5.SGD","IE00B2B36J28.USD","IE00B3PB1722.GBP","LU0912757837.SGD","LU0942090050.USD","LU2125909593.SGD","LU1430594728.SGD","LU0795875169.SGD","LU2089283258.USD","IXJ","FTXH","LU0098860793.USD","MEDX","LU0965509101.SGD","LU1989772840.SGD","JDOC","LABU","LU0289739699.SGD","LU0868494708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539450","title":"海西新藥(02637.HK)：HX9428治療新生血管性年齡相關性黃斑變性獲美國FDA IND批准啓動II期臨床試驗 同時在中國啓動第二項採用陽性對照的II期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539450","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656539450?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","IBBJ","PSYK","MDTX","LABU","BK4588","BK4585","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656460539","title":"海西新藥(02637)：HX9428治療新生血管性年齡相關性黃斑變性獲美國FDA IND批准啓動II期臨床試驗 同時在中國啓動第二項採用陽性對照的II期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2656460539","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656460539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834956,"startTime":"0","endTime":"0","summary":"此次获批的IND涵盖一项II期临床试验方案，旨在评估HX9428不同口服剂量在美国 nAMD患者中的有效性及安全性。该研究为集团在HX9428既往I 期及II期剂量扩展研究的基础上，进一步启动的一项随机、阳性对照的II期临床研究。本次美国FDAII期临床试验获批、中国标准疗法对照II期临床试验启动，标志着 HX9428全球临床开发进程取得重要进展，为全面验证HX9428在nAMD治疗中的临床价值奠定坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BMED","BK1191","PSYK","IND","MDTX","LABU","IBBJ","02637","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656210587","title":"美國 FDA 授予再鼎醫藥靶向 DLL3 抗體藥物偶聯物 Zocilurtatug Pelitecan（Zoci）孤兒藥資格認定，用於治療神經內分泌癌（NEC）","url":"https://stock-news.laohu8.com/highlight/detail?id=2656210587","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656210587?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 13:48","pubTimestamp":1785822480,"startTime":"0","endTime":"0","summary":"神经内分泌癌是一类高侵袭性恶性肿瘤，预后差且治疗选择有限，存在重大未被满足的临床需求 继欧洲药品管理局授予 zoci 孤儿药资格认定用于治疗肺神经内分泌癌之后，此次获美国 FDA 授予ODD，进一步印证了 zoci 在各类神经内分泌癌领域具有同类首创潜力 中国上海和美国马萨诸塞州剑桥2026年8月4日 /美通社/ -- 再鼎医药有限公司今日宣布，美国食品药品监督管理局已授予 zocilurtatug pelitecan孤儿药资格认定，用于治疗神经内分泌癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5018636_ZH18636_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5018636_ZH18636_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK1588","BK4585","LU2488822045.USD","ZLAB","BK1161","BK4526","BK4548","BK4139","LABU","BK4588","BK4531","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198971052","title":"醫療健康板塊快訊：市場動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1198971052","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198971052?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 04:56","pubTimestamp":1785790601,"startTime":"0","endTime":"0","summary":"分析师指出，尽管投资者此前主要担忧仿制药会蚕食其畅销抗癌药Somatuline的销售额，但瑞典Camurus公司的实验性药物CAM2029才是更长期的威胁。一项针对CAM2029治疗神经内分泌肿瘤的晚期研究结果将于2026年底或2027年初公布，分析人士认为，其结果很可能会优于Somatuline。考虑到Somatuline贡献了益普生约30%的销售额且利润极高，这无疑会给公司盈利带来巨大压力。Jefferies因此将益普生的评级从“持有”下调至“跑输大盘”。受此影响，其股价下跌8.2%，报153.50欧元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","XLV","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176302759","title":"醫療保健板塊綜述：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1176302759","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176302759?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 00:25","pubTimestamp":1785774322,"startTime":"0","endTime":"0","summary":"1007 ET - 杰富瑞分析师表示，益普生旗下最畅销的药物可能很快将面临来自瑞典卡穆鲁斯的竞争。投资者此前主要关注的是仿制药进入市场、侵蚀其旗舰抗癌药索马杜林销售的风险，但杰富瑞认为，更大的长期风险实则来自卡穆鲁斯的实验性药物CAM2029。杰富瑞随后将益普生的评级从“持有”下调至“跑输大盘”。益普生股价下跌8.2%，报153.50欧元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","BK4585","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656747793","title":"美國人已經為多肽而瘋狂，這是你可能關心的5個問題","url":"https://stock-news.laohu8.com/highlight/detail?id=2656747793","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656747793?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 17:47","pubTimestamp":1785750420,"startTime":"0","endTime":"0","summary":"但此次FDA咨询委员会投票的多肽，都是没有经过批准的产品，人们通过黑市或者长寿诊所私下购买，用来抗衰、恢复体力、改善睡眠、提升脑力等。但咨询委员会这一小步，是美国人为多肽疯狂的一大步。FDA官网显示，这届投票委员会小组共12人，至少8人是 2026年新获任命的，其中至少7名新任委员，与多肽产业有关联，或本身就是多肽政策的推动者。鉴于美国FDA在全球卫生体系中的影响力，此次对多肽开绿灯，后果也将波及全世界。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656191260&idx=3&sn=9447f651dbbeee189256ddf2f27cdd28&chksm=676248f6d0d526ebc910b879d3a514abec3d7e6450ac1abc85b3232a4b3f7c9744fda2a40f96&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4585","BK4009","HHS","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123567512","title":"醫療保健動態：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1123567512","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123567512?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 16:27","pubTimestamp":1785745649,"startTime":"0","endTime":"0","summary":"**0811 GMT** - 杰富瑞分析师指出，阿斯利康与百时美施贵宝之间潜在的合并交易，可能因双方产品组合重叠而面临反垄断障碍，并附带政治层面的考量。《金融时报》报道称两家公司曾进行合并谈判，阿斯利康对此不予置评，而百时美施贵宝未回应置评请求。此外，他们补充道，阿斯利康还需妥善处理交易的政治因素，以减少摩擦。欧洲早盘交易中，阿斯利康股价下跌6.2%。百时美施贵宝股价在美股盘前交易中上涨4.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4581","LABU","BK4588","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656329169","title":"天智航「蛇吞象式」收購拖累報表？三大疑問待解 遭投資者用腳投票","url":"https://stock-news.laohu8.com/highlight/detail?id=2656329169","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656329169?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 15:46","pubTimestamp":1785743160,"startTime":"0","endTime":"0","summary":"近日，天智航“蛇吞象式”收购复牌似乎遭投资者用脚投票，公司复牌第一个交易日收跌，当日跌幅为8.85%。截至此次预案签署日，此次交易的审计及评估工作尚未完成，标的资产估值及定价尚未确定。本次交易预计将达到《重组管理办法》规定的重大资产重组标准，从而构成上市公司重大资产重组。收购拖累报表叙事不性感？截止一季度末，天智航账面资金不足2亿元，资产负债率低于30%。若未来将其并表，是否可能进一步拖累天智航报表？","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-08-03/doc-inikzqsr2765691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HTEC","LABU","BK4585","KOMP","MDEV","ROBO","BK4588","PBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656239203","title":"醫渡科技(02158)聯合南大一附院發布兩款醫療健康智能體 賦能急救教學與心血管科普","url":"https://stock-news.laohu8.com/highlight/detail?id=2656239203","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656239203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 14:18","pubTimestamp":1785737891,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，医渡科技联合南昌大学第一附属医院发布急救教学智能体与“彭叔心视界”心血管数字医生科普智能体，其中“彭叔心视界”系全国首个心血管内科科普智能体。本项目是医渡科技与南大一附院合作的延伸，此前公司已为该院搭建了全院数据平台与科研平台，此次双方再次携手落地医疗AI中台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159760","IXJ","VHT","BK1518","LABU","02158","XBI","BK4550","BK1189","BK4585","XLV","BK4581","BK4588","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346943","title":"【今日主題前瞻】AI醫療健康解決方案市場規模2030年或突破1000億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346943","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346943?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 07:53","pubTimestamp":1785714782,"startTime":"0","endTime":"0","summary":" 据媒体报道，人工智能正加速融入诊疗的各个环节。据德勤《2025中国智慧医疗行业白皮书》预测，AI医疗健康解决方案市场规模2030年将突破1000亿元。AI医疗不是概念，而是正在加速扩容的新赛道。AI正从传统技术辅助工具，逐步升级为医疗产业“价值重塑”和“效率革命”的关键驱动力，其商业价值正在从研发端向临床端、支付端和患者端全面渗透。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260803/32323945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["CHAT","QTOC","XBI","VHT","ARTY","BK4585","XLV","159760","LABU","VTHR","BK4581","IXJ","BK4550","AIPO","AGIX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107798041","title":"醫療保健板塊速覽：市場動態追蹤","url":"https://stock-news.laohu8.com/highlight/detail?id=1107798041","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107798041?lang=zh_tw&edition=fundamental","pubTime":"2026-08-01 16:24","pubTimestamp":1785572678,"startTime":"0","endTime":"0","summary":"摩根大通分析师指出，该公司的新冠疫苗业务重心明显偏向下半年。他们在研究报告中写道：“我们并不认为市场会对本季度的营收数据给予过多关注。”至于管线进展，Moderna的新款诺如病毒疫苗在一项正在进行的后期试验中未能达到预期，而其新型季节性流感疫苗有望在8月5日获得批准。西门子医疗股价下跌0.3%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","BK4585","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399763","title":"諾華宣佈Pluvicto獲FDA批准用於PSMA陽性轉移性激素敏感性前列腺癌，有望推動轉移性前列腺癌治療新標準。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399763?lang=zh_tw&edition=fundamental","pubTime":"2026-08-01 04:26","pubTimestamp":1785529569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0070302665.USD","IE0002141913.USD","BK4007","IE00BJJMRZ35.SGD","LU0211331839.USD","LU0208291251.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4588","LU0320765489.SGD","PPH","BK4578","IE00B4R5TH58.HKD","NVS","BK4585","IE00BJT1NW94.SGD","BK4532","LABU","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361697","title":"Replimune抗癌療法獲FDA專家委員會支持，盤後股價飆升127%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361697","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655361697?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 21:18","pubTimestamp":1785503880,"startTime":"0","endTime":"0","summary":"生物技术公司Replimune Group周四盘后股价暴涨127%。此前，美国食品药品监督管理局的一个独立专家顾问委员会以10比3的投票结果，认为该公司实验性疗法RP1的关键临床研究数据可靠且具有临床意义。此次获得支持的RP1疗法，针对的是既往接受抗PD-1治疗后病情进展的晚期黑色素瘤患者。RP1的上市之路此前并不顺利，曾两次遭到FDA拒绝。Replimune首席执行官Sushil Patel表示，受此结果鼓舞，将继续与FDA合作推进审批工作。FDA预计将在2026年8月2日前做出最终审批决定。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-31/doc-iniktkaz4332413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655636397","title":"和諧健康被投保人告上法庭 原因竟是扣費失敗引起","url":"https://stock-news.laohu8.com/highlight/detail?id=2655636397","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655636397?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 18:59","pubTimestamp":1785495540,"startTime":"0","endTime":"0","summary":"2025年12月19日，和谐健康保险短信通知吴女士，续期缴费日为2025年12月26日，应交保费金额为3984元，同时提示其预存足额保费。吴女士称，在宽限期内和谐健康保险未通过短信、电话、邮件或其他可证明送达的有效方式进行催告。吴女士立即提出复效申请，和谐健康保险客服对其表示，保单已失效，复效需重新体检、重新核保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyx/2026-07-31/doc-iniktcuw9248499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4588","XLV","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655562893","title":"泰德醫藥(03880)成功完成HEPCLUDEX®原料藥之美國FDA上市許可前檢查(PLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655562893","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655562893?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 16:39","pubTimestamp":1785487145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，公司全资附属公司中肽生化有限公司位于中国杭州的现行生产质量管理规范生产设施，已成功通过由美国食品及药物管理局开展的上市许可前检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","IPOS","BK4585","03880","BK4588","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356774","title":"泰德醫藥(03880.HK)成功完成HEPCLUDEX®原料藥之美國FDA上市許可前檢查(PLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356774?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 16:39","pubTimestamp":1785487145,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LABU","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}